logo-loader
RNS
Venture Life Group

Venture Life Group - Sale of Non-Core Products

RNS Number : 7351K
Venture Life Group PLC
09 December 2025
 

THIS ANNOUNCEMENT WAS DEEMED BY THE COMPANY TO CONTAIN INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. WITH THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN

9 December 2025 

VENTURE LIFE GROUP PLC

("Venture Life" or the "Company")

Sale of non-core products for up to £4.5m in cash on a cash free, debt free basis

Venture Life (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces that, further to the disclosure made in the FY24 Final Results announcement, it has completed the sale of its Ultradex and Dentyl brands, including 100 per cent. of the issued share capital of Periproducts Limited, (the "Oral Care Assets") for an enterprise value of up to £4.5 million (the "Sale") on a cash free, debt free basis to Covestus Holdings Ltd.

 

The consideration for the Sale is payable in cash, with £3.75m paid to the Company on completion that is subject to customary working capital adjustments. A further amount of up to £0.75m will be payable in cash contingent upon the Oral Care Assets achieving expected trading results for the 12 months post completion. As part of the Sale, the Oral Care Assets and the Company will enter into a transitional services agreement until end of February 2026 to ensure a smooth transition.

 

The net proceeds of the Sale will further bolster Venture Life and its subsidiaries (the "Group") with additional financial resources for its acquisition strategy.

 

Strategic rationale

 

The Oral Care Assets do not form part of the future strategic direction of the Company and so the decision has been taken to divest of these assets. Venture Life is now focusing its efforts and resources on the Group's higher margin, higher growth core brands in its key target categories, to promote and support the Proactive Healthy Longevity of consumers. Its current core brands include Balance Activ, Health & Her/Him, Lift and Earol,  (collectively the "Power Brands"), and the funds raised through the Sale will be utilised alongside the existing available funds of the business to drive innovation and growth in the Power Brands, as well as to acquire interesting complementary brands with a pathway to profitable growth.

 

The Sale also presents the opportunity for the Board to further streamline the Company's operations and product portfolio through the disposal of non-core assets and to focus additional resources into the commercialisation, growth and development of the Power Brands. At the same time, it enables the Company to realise cash at a multiple of c.11x FY24 adjusted EBITDA, which it can redeploy both into the organic growth of its existing Power Brands and the acquisition of carefully selected, margin accretive, high growth assets within the Group's core categories of interest.

 

For the financial year ended 31 December 2024 the audited results of the Oral Care Assets generated revenues of £4.3 million and adjusted EBITDA of £0.4 million. As at 30 November 2025, the Oral Care Assets had a net carrying value of £4.5 million.

 

 

Jerry Randall, Chief Executive Officer, commented: "I am pleased that we have been able to divest of these non-core assets to a new owner that will continue to develop them. As we have indicated before these assets no longer form part of our strategic vision for Venture Life, so the divestment allows us to recycle the funds raised into our core focus categories and brands working out our 5-pillar strategic growth plan.

 

I am delighted with the post divestment progress since we disposed of our CDMO businesses earlier this year, and the collaboration with the Healthea Group (the purchasers of our CDMO businesses) where we are growing and strengthening the ongoing relationship for our mutual profitable growth. Aswell as generating significant funds for us to drive the growth of Venture Life, the divestment to the Healthea Group has also bought significant operational benefits including accelerated innovation opportunities and strengthened quality of supply. These two divestments have significantly simplified the Group and in conjunction with our new Microsoft D365 ERP system, which is now going live, we have a much more streamlined, agile and scalable business."

 

 

For further information, please contact:

 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer


 

Cavendish Capital Markets Limited (Nomad and Broker)

 

+44 (0) 20 7720 0500

Stephen Keys / George Lawson (Corporate Finance)

Michael Johnson (Sales)

 

 






About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, the Health and Her product range supporting the hormonal lifecycle, the UltraDEX and Dentyl oral care product ranges. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples and are sold in over 90 countries worldwide. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISFFFVFFFLTIIE
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Result of AGM

2 weeks ago

Total Voting Rights

2 weeks, 3 days ago

Transfer of Treasury Shares

3 weeks, 3 days ago

Transfer of Treasury Shares

3 weeks, 6 days ago

Total Voting Rights

on 10/01/2026

5 min read